Amgen (AMGN) Financials

$283.54 +5.14 (+1.85%)

Closing price 04:00 PM Eastern

Extended Trading

$282.58 -0.97 (-0.34%)

As of 07:57 PM Eastern

Annual Income Statements for Amgen

This table shows Amgen's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
Period end date	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018	12/31/2017	12/31/2016	12/31/2015
Net Income / (Loss) Attributable to Common Shareholders	4,090	6,717	6,552	5,893	7,264	7,842	8,394	1,979	7,722	6,939
Consolidated Net Income / (Loss)	4,090	6,717	6,552	5,893	7,264	7,842	8,394	1,979	7,722	6,939
Net Income / (Loss) Continuing Operations	4,090	6,717	6,552	5,893	7,264	7,842	8,394	1,979	7,722	6,939
Total Pre-Tax Income	4,609	7,855	7,346	6,701	8,133	9,138	9,545	9,597	9,163	7,978
Total Operating Income	7,258	7,897	9,566	7,639	9,139	9,674	10,263	9,973	9,794	8,470
Total Gross Profit	20,566	19,739	19,917	19,525	19,265	19,006	19,646	18,780	18,829	17,435
Total Revenue	33,424	28,190	26,323	25,979	25,424	23,362	23,747	22,849	22,991	21,662
Total Cost of Revenue	12,858	8,451	6,406	6,454	6,159	4,356	4,101	4,069	4,162	4,227
Operating Cost of Revenue	12,858	8,451	6,406	6,454	6,159	4,356	4,101	4,069	4,162	4,227
Total Operating Expenses	13,308	11,842	10,351	11,886	10,126	9,332	9,383	8,807	9,035	8,965
Selling, General & Admin Expense	7,344	7,058	5,917	5,562	5,919	5,216	5,646	5,245	5,195	4,895
Research & Development Expense	5,964	4,784	4,434	6,324	4,207	4,116	3,737	3,562	3,840	4,070
Total Other Income / (Expense), net	-2,649	-42	-2,220	-938	-1,006	-536	-718	-376	-631	-492
Interest Expense	3,155	2,875	1,406	1,197	1,262	1,289	1,392	1,304	1,260	1,095
Other Income / (Expense), net	506	2,833	-814	259	256	753	674	928	629	603
Income Tax Expense	519	1,138	794	808	869	1,296	1,151	7,618	1,441	1,039
Basic Earnings per Share	$7.62	$12.56	$12.18	$10.34	$12.40	$12.96	$12.70	$2.71	$10.32	$9.15
Weighted Average Basic Shares Outstanding	537M	535M	538M	570M	586M	605M	661M	731M	748M	758M
Diluted Earnings per Share	$7.56	$12.49	$12.11	$10.28	$12.31	$12.88	$12.62	$2.69	$10.24	$9.06
Weighted Average Diluted Shares Outstanding	541M	538M	541M	573M	590M	609M	665M	735M	754M	766M
Weighted Average Basic & Diluted Shares Outstanding	537.20M	535.92M	533.98M	557.03M	577.57M	589.81M	660.90M	730.30M	748.30M	758.40M
Cash Dividends to Common per Share	$9.13	-	-	$7.04	$6.40	$5.80	$5.28	$4.60	$4.00	$3.16

This table shows Amgen's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	3/31/2025	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Net Income / (Loss) Attributable to Common Shareholders	1,730	627	2,830	746	-113	767	1,730	1,379	2,841	1,616	2,143
Consolidated Net Income / (Loss)	1,730	627	2,830	746	-113	767	1,730	1,379	2,841	1,616	2,143
Net Income / (Loss) Continuing Operations	1,730	627	2,830	746	-113	767	1,730	1,379	2,841	1,616	2,143
Total Pre-Tax Income	1,973	782	3,101	794	-68	852	1,947	1,614	3,442	1,748	2,392
Total Operating Income	1,178	2,311	2,047	1,909	991	1,271	2,021	2,684	1,921	2,230	2,660
Total Gross Profit	5,181	5,974	5,193	5,152	4,247	5,084	5,097	5,173	4,385	5,092	5,064
Total Revenue	8,149	9,086	8,503	8,388	7,447	8,196	6,903	6,986	6,105	6,839	6,652
Total Cost of Revenue	2,968	3,112	3,310	3,236	3,200	3,112	1,806	1,813	1,720	1,747	1,588
Operating Cost of Revenue	2,968	3,112	3,310	3,236	3,200	3,112	1,806	1,813	1,720	1,747	1,588
Total Operating Expenses	4,003	3,663	3,146	3,243	3,256	3,813	3,076	2,489	2,464	2,862	2,404
Selling, General & Admin Expense	2,517	2,126	1,625	1,785	1,808	3,153	1,353	1,294	1,258	2,075	1,287
Research & Development Expense	1,486	1,724	1,450	1,447	1,343	1,534	1,079	1,113	1,058	1,324	1,112
Total Other Income / (Expense), net	795	-1,529	1,054	-1,115	-1,059	-419	-74	-1,070	1,521	-482	-268
Interest Expense	723	747	776	808	824	821	759	752	543	415	368
Other Income / (Expense), net	1,518	-782	1,830	-307	-235	402	685	-318	2,064	-67	100
Income Tax Expense	243	155	271	48	45	85	217	235	601	132	249
Basic Earnings per Share	$3.22	$1.17	$5.27	$1.39	($0.21)	$1.43	$3.23	$2.58	$5.32	$3.02	$4.01
Weighted Average Basic Shares Outstanding	538M	537M	537M	537M	536M	535M	535M	535M	534M	538M	535M
Diluted Earnings per Share	$3.20	$1.17	$5.22	$1.38	($0.21)	$1.42	$3.22	$2.57	$5.28	$3.00	$3.98
Weighted Average Diluted Shares Outstanding	541M	541M	542M	541M	536M	538M	538M	537M	538M	541M	538M
Weighted Average Basic & Diluted Shares Outstanding	537.71M	537.20M	537.53M	537.33M	536.43M	535.92M	535.18M	534.90M	534.33M	533.98M	533.58M
Cash Dividends to Common per Share	$2.38	-	$2.25	-	$2.25	-	$2.13	-	$2.13	-	$1.94

This table details how cash moves in and out of Amgen's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
Period end date	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018	12/31/2017	12/31/2016	12/31/2015
Net Change in Cash & Equivalents	1,029	3,315	-360	1,723	229	-908	3,145	559	-903	413
Net Cash From Operating Activities	11,490	8,471	9,721	9,261	10,497	9,150	11,296	11,177	10,354	9,731
Net Cash From Continuing Operating Activities	11,490	8,471	9,721	9,261	10,497	8,842	11,296	10,509	10,354	9,731
Net Income / (Loss) Continuing Operations	4,090	6,717	6,552	5,893	7,264	7,842	8,394	1,979	7,722	6,939
Consolidated Net Income / (Loss)	4,090	6,717	6,552	5,893	7,264	7,842	8,394	1,979	7,722	6,939
Depreciation Expense	5,592	4,071	3,417	3,398	3,601	2,206	1,946	1,955	2,105	2,108
Non-Cash Adjustments To Reconcile Net Income	671	-560	1,683	1,617	135	-186	697	663	343	176
Changes in Operating Assets and Liabilities, net	1,137	-1,757	-1,931	-1,647	-503	-1,020	259	6,580	184	508
Net Cash From Investing Activities	-1,046	-26,204	-6,044	733	-5,401	5,709	14,339	-4,024	-8,658	-5,547
Net Cash From Continuing Investing Activities	-1,046	-26,204	-6,044	733	-5,401	5,709	14,339	-4,024	-8,658	-5,547
Purchase of Property, Plant & Equipment	-1,096	-1,112	-936	-880	-608	-618	-738	-664	-738	-594
Acquisitions	0.00	-26,989	-3,839	-2,529	-3,219	-13,641	-40	-19	0.00	-359
Purchase of Investments	0.00	-1.00	-2,587	-8,900	-8,477	-9,394	-18,741	-33,607	-28,094	-25,977
Sale and/or Maturity of Investments	0.00	1,673	1,218	13,234	6,978	29,390	33,768	30,414	20,417	21,556
Other Investing Activities, net	50	225	100	-192	-75	-28	-105	-148	-243	-447
Net Cash From Financing Activities	-9,415	21,048	-4,037	-8,271	-4,867	-15,767	-22,490	-6,594	-2,599	-3,771
Net Cash From Continuing Financing Activities	-9,415	21,048	-4,037	-8,271	-4,867	-15,767	-22,490	-6,594	-2,599	-3,771
Repayment of Debt	-4,383	-2,173	-400	-4,228	-6,540	-4,556	-1,189	-4,405	-	-2,319
Repurchase of Common Equity	-200	0.00	-6,360	-4,975	-3,486	-7,702	-17,794	-3,160	-	-1,867
Payment of Dividends	-4,832	-4,556	-4,196	-4,013	-3,755	-3,509	-3,507	-3,365	-	-2,396
Issuance of Debt	0.00	27,777	6,919	4,945	8,914	0.00	0.00	4,527	-	3,465

This table details how cash moves in and out of Amgen's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	3/31/2025	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Net Change in Cash & Equivalents	-3,163	2,962	-290	-407	-1,236	-23,797	493	2,688	23,931	-1,873	4,299
Net Cash From Operating Activities	1,391	4,771	3,571	2,459	689	538	2,760	4,109	1,064	2,649	2,978
Net Cash From Continuing Operating Activities	1,391	4,771	3,571	2,459	689	538	2,760	4,109	1,064	2,649	2,978
Net Income / (Loss) Continuing Operations	1,730	627	2,830	746	-113	767	1,730	1,379	2,841	1,616	2,143
Consolidated Net Income / (Loss)	1,730	627	2,830	746	-113	767	1,730	1,379	2,841	1,616	2,143
Depreciation Expense	1,387	1,397	1,396	1,400	1,399	1,380	895	896	900	911	837
Non-Cash Adjustments To Reconcile Net Income	-460	1,002	-1,401	574	496	-88	529	873	-1,874	169	21
Changes in Operating Assets and Liabilities, net	-1,266	1,745	746	-261	-1,093	-1,521	-394	961	-803	-47	-23
Net Cash From Investing Activities	-447	-402	-210	-217	-217	-27,089	-262	-211	1,358	-3,473	-267
Net Cash From Continuing Investing Activities	-447	-402	-210	-217	-217	-27,089	-262	-211	1,358	-3,473	-267
Purchase of Property, Plant & Equipment	-411	-371	-257	-238	-230	-249	-248	-271	-344	-340	-160
Other Investing Activities, net	-36	-31	47	21	13	152	-14	59	28	159	-120
Net Cash From Financing Activities	-4,107	-1,407	-3,651	-2,649	-1,708	2,754	-2,005	-1,210	21,509	-1,049	1,588
Net Cash From Continuing Financing Activities	-4,107	-1,407	-3,651	-2,649	-1,708	2,754	-2,005	-1,210	21,509	-1,049	1,588
Repayment of Debt	-2,828	-2.00	-2,441	-1,440	-500	-102	-866	-53	-1,152	10	-358
Payment of Dividends	-1,279	-1,205	-1,210	-1,209	-1,208	-1,140	-1,140	-1,139	-1,137	-1,040	-1,038

This table presents Amgen's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
Period end date	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018	12/31/2017	12/31/2016	12/31/2015
Total Assets	91,839	97,154	65,121	61,165	62,948	59,707	66,416	79,954	77,626	71,449
Total Current Assets	29,030	30,332	22,186	19,385	21,144	18,440	37,618	49,476	46,010	38,515
Cash & Equivalents	11,973	10,944	7,629	7,989	6,266	6,037	6,945	3,800	3,241	4,144
Accounts Receivable	6,782	7,268	5,563	4,895	4,525	4,057	3,580	3,237	3,165	2,995
Inventories, net	6,998	9,518	4,930	4,086	3,893	3,584	2,940	2,834	2,745	2,435
Other Current Assets	3,277	2,602	2,388	2,367	2,079	1,888	1,794	1,727	2,015	1,703
Plant, Property, & Equipment, net	6,543	5,941	5,427	5,184	4,889	4,928	4,958	4,989	4,961	4,907
Total Noncurrent Assets	56,266	60,881	37,508	36,596	36,915	36,339	23,840	25,489	26,655	28,027
Goodwill	18,637	18,629	15,529	14,890	14,689	14,703	14,699	14,761	14,751	14,787
Intangible Assets	27,699	32,641	16,080	15,182	16,587	19,413	7,443	8,609	10,279	11,641
Other Noncurrent Operating Assets	9,930	9,611	5,899	6,524	5,639	2,223	1,698	2,119	1,625	1,599
Total Liabilities & Shareholders' Equity	91,839	97,154	65,121	61,165	62,948	59,707	66,416	79,954	77,626	71,449
Total Liabilities	85,962	90,922	61,460	54,465	53,539	50,034	53,916	54,713	47,751	43,366
Total Current Liabilities	23,099	18,392	15,687	12,184	11,653	12,835	13,488	9,020	11,204	8,664
Short-Term Debt	3,550	1,443	1,591	87	91	2,953	4,419	1,152	4,403	2,247
Accounts Payable	1,908	1,590	1,572	1,366	1,421	1,371	1,207	1,352	917	965
Accrued Expenses	17,641	15,359	12,524	10,731	10,141	8,511	7,862	6,516	5,884	5,452
Total Noncurrent Liabilities	62,863	72,530	45,773	42,281	41,886	37,199	40,428	45,693	36,547	34,702
Long-Term Debt	56,549	63,170	37,354	33,222	32,895	26,950	29,510	34,190	30,193	29,182
Noncurrent Deferred & Payable Income Tax Liabilities	3,965	7,034	5,768	6,594	6,968	8,037	9,634	10,265	4,855	4,212
Other Noncurrent Operating Liabilities	2,349	2,326	2,651	2,465	2,023	2,212	1,284	1,238	1,499	1,308
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	5,877	6,232	3,661	6,700	9,409	9,673	12,500	25,241	29,875	28,083
Total Preferred & Common Equity	5,877	6,232	3,661	6,700	9,409	9,673	12,500	25,241	29,875	28,083
Total Common Equity	5,877	6,232	3,661	6,700	9,409	9,673	12,500	25,241	29,875	28,083
Common Stock	33,533	33,070	32,514	32,096	31,802	31,531	31,246	30,992	30,784	30,649
Retained Earnings	-27,590	-26,549	-28,622	-24,600	-21,408	-21,330	-17,977	-5,072	-438	-2,086
Accumulated Other Comprehensive Income / (Loss)	-66	-289	-231	-796	-985	-528	-769	-679	-471	-480

This table presents Amgen's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	3/31/2025	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Total Assets	89,367	91,839	90,883	90,907	92,980	97,154	90,534	90,269	88,720	65,121	63,700
Total Current Assets	26,929	29,030	26,766	27,206	28,029	30,332	48,477	47,380	44,703	22,186	24,062
Cash & Equivalents	8,810	11,973	9,011	9,301	9,708	10,944	34,741	34,248	31,560	7,629	9,502
Accounts Receivable	8,132	6,782	7,317	6,934	6,776	7,268	6,145	5,830	5,736	5,563	5,326
Inventories, net	6,729	6,998	7,362	7,995	8,724	9,518	5,026	4,978	5,011	4,930	4,757
Other Current Assets	3,258	3,277	3,076	2,976	2,821	2,602	2,565	2,324	2,395	2,388	2,501
Plant, Property, & Equipment, net	6,681	6,543	6,156	6,097	6,002	5,941	5,563	5,532	5,460	5,427	5,188
Total Noncurrent Assets	55,757	56,266	57,961	57,604	58,949	60,881	36,494	37,357	38,557	37,508	34,450
Goodwill	18,645	18,637	18,658	18,616	18,570	18,629	15,509	15,531	15,531	15,529	14,845
Intangible Assets	25,724	27,699	28,920	30,172	31,372	32,641	13,150	14,633	15,393	16,080	13,266
Other Noncurrent Operating Assets	11,388	9,930	10,383	8,816	9,007	9,611	7,835	7,193	7,633	5,899	6,339
Total Liabilities & Shareholders' Equity	89,367	91,839	90,883	90,907	92,980	97,154	90,534	90,269	88,720	65,121	63,700
Total Liabilities	83,160	85,962	83,356	84,982	87,958	90,922	82,878	83,488	83,372	61,460	60,047
Total Current Liabilities	23,008	23,099	20,312	21,517	19,714	18,392	16,954	17,097	14,215	15,687	14,331
Short-Term Debt	3,368	3,550	3,544	5,528	3,959	1,443	1,428	2,167	834	1,591	1,543
Accounts Payable	2,406	1,908	2,147	2,267	1,628	1,590	1,358	1,212	1,320	1,572	1,204
Accrued Expenses	17,234	17,641	14,621	13,722	14,127	15,359	14,168	13,718	12,061	12,524	11,584
Total Noncurrent Liabilities	60,152	62,863	63,044	63,465	68,244	72,530	65,924	66,391	69,157	45,773	45,716
Long-Term Debt	54,013	56,549	56,854	57,117	60,061	63,170	59,040	59,377	60,761	37,354	37,161
Noncurrent Deferred & Payable Income Tax Liabilities	3,929	3,965	3,991	3,985	5,826	7,034	4,579	4,478	5,864	5,768	5,680
Other Noncurrent Operating Liabilities	2,210	2,349	2,199	2,363	2,357	2,326	2,305	2,536	2,532	2,651	2,875
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	6,207	5,877	7,527	5,925	5,022	6,232	7,656	6,781	5,348	3,661	3,653
Total Preferred & Common Equity	6,207	5,877	7,527	5,925	5,022	6,232	7,656	6,781	5,348	3,661	3,653
Total Common Equity	6,207	5,877	7,527	5,925	5,022	6,232	7,656	6,781	5,348	3,661	3,653
Common Stock	33,578	33,533	33,393	33,204	33,082	33,070	32,753	32,601	32,535	32,514	32,371
Retained Earnings	-27,140	-27,590	-25,530	-27,124	-27,870	-26,549	-24,971	-25,540	-26,919	-28,622	-28,066
Accumulated Other Comprehensive Income / (Loss)	-231	-66	-336	-155	-190	-289	-126	-280	-268	-231	-652

This table displays calculated financial ratios and metrics derived from Amgen's official financial filings.

Metric	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
Period end date	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018	12/31/2017	12/31/2016	12/31/2015
Growth Metrics	-	-	-	-	-	-	-	-	-	-
Revenue Growth	18.57%	7.09%	1.32%	2.18%	8.83%	-1.62%	3.93%	-0.62%	6.14%	7.97%
EBITDA Growth	-9.76%	21.63%	7.73%	-13.08%	2.87%	-1.94%	0.21%	2.62%	12.05%	27.81%
EBIT Growth	-27.64%	22.60%	10.81%	-15.93%	-9.90%	-4.66%	0.33%	4.59%	14.88%	36.31%
NOPAT Growth	-4.62%	-20.85%	27.00%	-17.70%	-1.68%	-8.02%	338.87%	-75.08%	12.04%	28.84%
Net Income Growth	-39.11%	2.52%	11.18%	-18.87%	-7.37%	-6.58%	324.15%	-74.37%	11.28%	34.53%
EPS Growth	-39.47%	3.14%	17.80%	-16.49%	-4.43%	2.06%	369.15%	-73.73%	13.02%	35.22%
Operating Cash Flow Growth	35.64%	-12.86%	4.97%	-11.77%	14.72%	-19.00%	1.06%	7.95%	6.40%	8.70%
Free Cash Flow Firm Growth	162.17%	-375.54%	10.92%	-8.27%	235.16%	-148.48%	13.29%	-4.60%	14.87%	13.60%
Invested Capital Growth	-9.85%	79.88%	4.16%	0.71%	3.53%	79.07%	-9.42%	-28.35%	-6.20%	-4.54%
Revenue Q/Q Growth	2.74%	5.06%	-0.03%	0.82%	1.75%	-0.14%	1.84%	-0.71%	1.90%	0.96%
EBITDA Q/Q Growth	-0.94%	-0.14%	-1.97%	2.26%	0.64%	-0.32%	0.25%	-1.34%	3.56%	6.34%
EBIT Q/Q Growth	-1.82%	-4.37%	-3.35%	3.55%	-0.94%	-2.37%	-0.08%	-0.59%	4.14%	7.72%
NOPAT Q/Q Growth	14.58%	-11.80%	0.08%	5.16%	-0.35%	-3.96%	287.53%	-76.20%	2.40%	6.61%
Net Income Q/Q Growth	-3.31%	-11.22%	-4.14%	5.06%	-1.20%	-2.79%	281.20%	-75.80%	1.78%	7.87%
EPS Q/Q Growth	-3.20%	-11.23%	-2.65%	5.87%	-0.81%	-1.30%	230.37%	-75.66%	2.30%	8.11%
Operating Cash Flow Q/Q Growth	58.33%	-19.95%	-1.61%	7.61%	-3.32%	-6.92%	1.64%	-0.78%	11.01%	-7.32%
Free Cash Flow Firm Q/Q Growth	161.97%	-485.17%	-31.54%	1.47%	246.57%	-168.61%	6.69%	-5.60%	16.90%	2.02%
Invested Capital Q/Q Growth	-8.34%	79.44%	7.84%	-2.75%	-3.46%	54.37%	-9.18%	-29.07%	-6.15%	-1.67%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-
Gross Margin	61.53%	70.02%	75.66%	75.16%	75.77%	81.35%	82.73%	82.19%	81.90%	80.49%
EBITDA Margin	39.96%	52.50%	46.23%	43.48%	51.12%	54.08%	54.25%	56.27%	54.49%	51.62%
Operating Margin	21.71%	28.01%	36.34%	29.40%	35.95%	41.41%	43.22%	43.65%	42.60%	39.10%
EBIT Margin	23.23%	38.06%	33.25%	30.40%	36.95%	44.63%	46.06%	47.71%	45.34%	41.88%
Profit (Net Income) Margin	12.24%	23.83%	24.89%	22.68%	28.57%	33.57%	35.35%	8.66%	33.59%	32.03%
Tax Burden Percent	88.74%	85.51%	89.19%	87.94%	89.32%	85.82%	87.94%	20.62%	84.27%	86.98%
Interest Burden Percent	59.36%	73.21%	83.94%	84.84%	86.57%	87.64%	87.27%	88.04%	87.91%	87.93%
Effective Tax Rate	11.26%	14.49%	10.81%	12.06%	10.68%	14.18%	12.06%	79.38%	15.73%	13.02%
Return on Invested Capital (ROIC)	11.31%	14.49%	26.14%	21.09%	26.16%	34.74%	50.10%	9.08%	30.28%	25.58%
ROIC Less NNEP Spread (ROIC-NNEP)	6.69%	14.40%	18.93%	17.62%	22.01%	31.15%	123.91%	10.66%	61.18%	2.67%
Return on Net Nonoperating Assets (RNNOA)	56.24%	121.30%	100.33%	52.08%	49.98%	35.99%	-5.62%	-1.90%	-3.63%	0.19%
Return on Equity (ROE)	67.55%	135.79%	126.47%	73.16%	76.13%	70.73%	44.48%	7.18%	26.65%	25.77%
Cash Return on Invested Capital (CROIC)	21.67%	-42.59%	22.07%	20.38%	22.69%	-21.92%	59.98%	42.12%	36.68%	30.22%
Operating Return on Assets (OROA)	8.22%	13.22%	13.86%	12.73%	15.32%	16.53%	14.94%	13.84%	13.98%	12.92%
Return on Assets (ROA)	4.33%	8.28%	10.38%	9.50%	11.84%	12.44%	11.47%	2.51%	10.36%	9.88%
Return on Common Equity (ROCE)	67.55%	135.79%	126.47%	73.16%	76.13%	70.73%	44.48%	7.18%	26.65%	25.77%
Return on Equity Simple (ROE_SIMPLE)	69.59%	107.78%	178.97%	87.96%	77.20%	81.07%	67.15%	7.84%	25.85%	24.71%
Net Operating Profit after Tax (NOPAT)	6,441	6,753	8,532	6,718	8,163	8,302	9,025	2,057	8,254	7,367
NOPAT Margin	19.27%	23.96%	32.41%	25.86%	32.11%	35.54%	38.01%	9.00%	35.90%	34.01%
Net Nonoperating Expense Percent (NNEP)	4.62%	0.09%	7.21%	3.47%	4.15%	3.59%	-73.81%	-1.58%	-30.90%	22.91%
Return On Investment Capital (ROIC_SIMPLE)	9.76%	9.53%	20.03%	-	-	-	-	-	-	-
Cost of Revenue to Revenue	38.47%	29.98%	24.34%	24.84%	24.23%	18.65%	17.27%	17.81%	18.10%	19.51%
SG&A Expenses to Revenue	21.97%	25.04%	22.48%	21.41%	23.28%	22.33%	23.78%	22.96%	22.60%	22.60%
R&D to Revenue	17.84%	16.97%	16.84%	24.34%	16.55%	17.62%	15.74%	15.59%	16.70%	18.79%
Operating Expenses to Revenue	39.82%	42.01%	39.32%	45.75%	39.83%	39.95%	39.51%	38.54%	39.30%	41.39%
Earnings before Interest and Taxes (EBIT)	7,764	10,730	8,752	7,898	9,395	10,427	10,937	10,901	10,423	9,073
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	13,356	14,801	12,169	11,296	12,996	12,633	12,883	12,856	12,528	11,181
Valuation Ratios	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	23.65	23.82	35.62	17.34	12.55	12.72	8.27	4.05	2.87	3.35
Price to Tangible Book Value (P/TBV)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	54.63	17.68	56.78
Price to Revenue (P/Rev)	4.16	5.27	4.95	4.47	4.65	5.27	4.35	4.47	3.73	4.34
Price to Earnings (P/E)	33.98	22.10	19.91	19.71	16.26	15.69	12.32	51.65	11.09	13.54
Dividend Yield	3.48%	3.07%	3.17%	4.27%	3.15%	2.80%	3.25%	3.27%	3.47%	2.54%
Earnings Yield	2.94%	4.53%	5.02%	5.07%	6.15%	6.37%	8.12%	1.94%	9.01%	7.38%
Enterprise Value to Invested Capital (EV/IC)	3.46	3.37	4.81	4.42	4.42	4.70	6.31	5.07	3.11	3.34
Enterprise Value to Revenue (EV/Rev)	5.60	7.17	6.08	5.44	5.53	6.16	4.55	4.20	3.57	4.34
Enterprise Value to EBITDA (EV/EBITDA)	14.01	13.65	13.15	12.52	10.81	11.40	8.38	7.46	6.56	8.41
Enterprise Value to EBIT (EV/EBIT)	24.10	18.83	18.29	17.91	14.95	13.81	9.88	8.79	7.88	10.36
Enterprise Value to NOPAT (EV/NOPAT)	29.05	29.93	18.76	21.05	17.21	17.35	11.97	46.62	9.96	12.76
Enterprise Value to Operating Cash Flow (EV/OCF)	16.28	23.86	16.47	15.27	13.38	15.74	9.56	8.58	7.94	9.66
Enterprise Value to Free Cash Flow (EV/FCFF)	15.16	0.00	22.22	21.78	19.84	0.00	10.00	10.05	8.22	10.80
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-
Debt to Equity	10.23	10.37	10.64	4.97	3.51	3.09	2.71	1.40	1.16	1.12
Long-Term Debt to Equity	9.62	10.14	10.20	4.96	3.50	2.79	2.36	1.35	1.01	1.04
Financial Leverage	8.41	8.42	5.30	2.96	2.27	1.16	-0.05	-0.18	-0.06	0.07
Leverage Ratio	15.61	16.40	12.19	7.70	6.43	5.69	3.88	2.86	2.57	2.61
Compound Leverage Factor	9.27	12.01	10.23	6.54	5.56	4.99	3.38	2.52	2.26	2.29
Debt to Total Capital	91.09%	91.20%	91.41%	83.25%	77.81%	75.56%	73.08%	58.34%	53.66%	52.81%
Short-Term Debt to Total Capital	5.38%	2.04%	3.73%	0.22%	0.21%	7.46%	9.52%	1.90%	6.83%	3.78%
Long-Term Debt to Total Capital	85.71%	89.17%	87.67%	83.04%	77.59%	68.10%	63.56%	56.44%	46.83%	49.04%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	8.91%	8.80%	8.59%	16.75%	22.19%	24.44%	26.92%	41.66%	46.34%	47.19%
Debt to EBITDA	4.50	4.37	3.20	2.95	2.54	2.37	2.63	2.75	2.76	2.81
Net Debt to EBITDA	3.60	3.63	2.44	2.24	1.72	1.66	0.36	-0.49	-0.28	0.00
Long-Term Debt to EBITDA	4.23	4.27	3.07	2.94	2.53	2.13	2.29	2.66	2.41	2.61
Debt to NOPAT	9.33	9.57	4.56	4.96	4.04	3.60	3.76	17.19	4.19	4.27
Net Debt to NOPAT	7.47	7.95	3.47	3.76	2.74	2.53	0.51	-3.08	-0.42	0.01
Long-Term Debt to NOPAT	8.78	9.35	4.38	4.95	4.03	3.25	3.27	16.63	3.66	3.96
Altman Z-Score	1.27	1.40	1.63	1.71	1.93	2.06	2.11	2.37	2.35	2.48
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-
Current Ratio	1.26	1.65	1.41	1.59	1.81	1.44	2.79	5.49	4.11	4.45
Quick Ratio	0.81	0.99	0.95	1.06	1.30	1.01	2.44	4.98	3.68	3.97
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	12,339	-19,847	7,203	6,494	7,080	-5,238	10,805	9,538	9,998	8,704
Operating Cash Flow to CapEx	1,048.36%	761.78%	1,038.57%	1,052.39%	1,726.48%	1,480.58%	1,530.62%	1,683.28%	1,402.98%	3,040.94%
Free Cash Flow to Firm to Interest Expense	3.91	-6.90	5.12	5.43	5.61	-4.06	7.76	7.31	7.93	7.95
Operating Cash Flow to Interest Expense	3.64	2.95	6.91	7.74	8.32	7.10	8.11	8.57	8.22	8.89
Operating Cash Flow Less CapEx to Interest Expense	3.29	2.56	6.25	7.00	7.84	6.62	7.58	8.06	7.63	8.59
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.35	0.35	0.42	0.42	0.41	0.37	0.32	0.29	0.31	0.31
Accounts Receivable Turnover	4.76	4.39	5.03	5.52	5.93	6.12	6.97	7.14	7.46	7.82
Inventory Turnover	1.56	1.17	1.42	1.62	1.65	1.34	1.42	1.46	1.61	1.66
Fixed Asset Turnover	5.35	4.96	4.96	5.16	5.18	4.73	4.77	4.59	4.66	4.28
Accounts Payable Turnover	7.35	5.35	4.36	4.63	4.41	3.38	3.21	3.59	4.42	4.31
Days Sales Outstanding (DSO)	76.72	83.07	72.51	66.17	61.60	59.66	52.39	51.13	48.90	46.68
Days Inventory Outstanding (DIO)	234.42	312.01	256.86	225.62	221.55	273.33	256.95	250.23	227.14	219.41
Days Payable Outstanding (DPO)	49.65	68.28	83.70	78.81	82.73	108.01	113.88	101.77	82.52	84.62
Cash Conversion Cycle (CCC)	261.49	326.79	245.66	212.99	200.43	224.98	195.46	199.59	193.51	181.47
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-
Invested Capital	54,003	59,901	33,301	31,972	31,748	30,665	17,125	18,905	26,386	28,130
Invested Capital Turnover	0.59	0.60	0.81	0.82	0.81	0.98	1.32	1.01	0.84	0.75
Increase / (Decrease) in Invested Capital	-5,898	26,600	1,329	224	1,083	13,540	-1,780	-7,481	-1,744	-1,337
Enterprise Value (EV)	187,106	202,091	160,059	141,435	140,468	144,006	108,013	95,872	82,179	94,013
Market Capitalization	138,980	148,422	130,419	116,163	118,129	123,014	103,388	102,208	85,668	93,966
Book Value per Share	$10.93	$11.64	$6.86	$11.89	$16.16	$16.28	$19.62	$34.77	$40.16	$37.23
Tangible Book Value per Share	($75.27)	($84.16)	($52.38)	($41.49)	($37.56)	($41.14)	($15.13)	$2.58	$6.51	$2.19
Total Capital	65,976	70,845	42,606	40,009	42,395	39,576	46,429	60,583	64,471	59,512
Total Debt	60,099	64,613	38,945	33,309	32,986	29,903	33,929	35,342	34,596	31,429
Total Long-Term Debt	56,549	63,170	37,354	33,222	32,895	26,950	29,510	34,190	30,193	29,182
Net Debt	48,126	53,669	29,640	25,272	22,339	20,992	4,625	-6,336	-3,489	47
Capital Expenditures (CapEx)	1,096	1,112	936	880	608	618	738	664	738	320
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-2,492	2,439	-1,215	-749	-1,065	-353	-755	-70	1,124	716
Debt-free Net Working Capital (DFNWC)	9,481	13,383	8,090	7,288	9,582	8,558	28,549	41,608	39,209	32,098
Net Working Capital (NWC)	5,931	11,940	6,499	7,201	9,491	5,605	24,130	40,456	34,806	29,851
Net Nonoperating Expense (NNE)	2,351	36	1,980	825	899	460	631	78	532	428
Net Nonoperating Obligations (NNO)	48,126	53,669	29,640	25,272	22,339	20,992	4,625	-6,336	-3,489	47
Total Depreciation and Amortization (D&A)	5,592	4,071	3,417	3,398	3,601	2,206	1,946	1,955	2,105	2,108
Debt-free, Cash-free Net Working Capital to Revenue	-7.46%	8.65%	-4.62%	-2.88%	-4.19%	-1.51%	-3.18%	-0.31%	4.89%	3.31%
Debt-free Net Working Capital to Revenue	28.37%	47.47%	30.73%	28.05%	37.69%	36.63%	120.22%	182.10%	170.54%	148.18%
Net Working Capital to Revenue	17.74%	42.36%	24.69%	27.72%	37.33%	23.99%	101.61%	177.06%	151.39%	137.80%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	$7.62	$12.56	$12.18	$10.34	$12.40	$12.96	$12.70	$2.71	$10.32	$9.15
Adjusted Weighted Average Basic Shares Outstanding	537M	535M	538M	570M	586M	605M	661M	731M	748M	758M
Adjusted Diluted Earnings per Share	$7.56	$12.49	$12.11	$10.28	$12.31	$12.88	$12.62	$2.69	$10.24	$9.06
Adjusted Weighted Average Diluted Shares Outstanding	541M	538M	541M	573M	590M	609M	665M	735M	754M	766M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	537.20M	535.92M	533.98M	557.03M	577.57M	589.81M	622.28M	720.56M	736.45M	752.09M
Normalized Net Operating Profit after Tax (NOPAT)	6,441	6,753	8,532	6,718	8,163	8,302	9,025	6,981	8,254	7,367
Normalized NOPAT Margin	19.27%	23.96%	32.41%	25.86%	32.11%	35.54%	38.01%	30.55%	35.90%	34.01%
Pre Tax Income Margin	13.79%	27.86%	27.91%	25.79%	31.99%	39.11%	40.19%	42.00%	39.85%	36.83%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	2.46	3.73	6.22	6.60	7.44	8.09	7.86	8.36	8.27	8.29
NOPAT to Interest Expense	2.04	2.35	6.07	5.61	6.47	6.44	6.48	1.58	6.55	6.73
EBIT Less CapEx to Interest Expense	2.11	3.35	5.56	5.86	6.96	7.61	7.33	7.85	7.69	7.99
NOPAT Less CapEx to Interest Expense	1.69	1.96	5.40	4.88	5.99	5.96	5.95	1.07	5.96	6.44
Payout Ratios	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	118.14%	67.83%	64.04%	68.10%	51.69%	44.75%	41.78%	170.04%	0.00%	34.53%
Augmented Payout Ratio	123.03%	67.83%	161.11%	152.52%	99.68%	142.96%	253.76%	329.71%	0.00%	61.44%

This table displays calculated financial ratios and metrics derived from Amgen's official financial filings.

Metric	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	3/31/2025	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Revenue Growth	9.43%	10.86%	23.18%	20.07%	21.98%	19.84%	3.77%	5.94%	-2.13%	-0.10%	-0.81%
EBITDA Growth	89.47%	-4.16%	46.43%	-7.97%	-55.89%	-0.68%	0.11%	21.40%	73.78%	-7.35%	8.97%
EBIT Growth	256.61%	-8.61%	43.27%	-32.29%	-81.03%	-22.65%	-1.96%	27.27%	102.28%	-12.29%	12.61%
NOPAT Growth	48.90%	61.94%	4.03%	-21.79%	-56.25%	-44.50%	-24.65%	22.51%	-28.03%	0.41%	14.63%
Net Income Growth	1,630.97%	-18.25%	63.58%	-45.90%	-103.98%	-52.54%	-19.27%	4.71%	92.48%	-14.90%	13.75%
EPS Growth	1,623.81%	-17.61%	62.11%	-46.30%	-103.98%	-52.67%	-19.10%	4.90%	97.01%	-9.91%	20.24%
Operating Cash Flow Growth	101.89%	786.80%	29.38%	-40.16%	-35.24%	-79.69%	-7.32%	112.90%	-50.83%	-5.66%	23.16%
Free Cash Flow Firm Growth	124.03%	130.45%	-3,241.05%	-90,615.89%	-804.84%	-3,574.71%	-116.17%	-100.84%	-205.78%	-59.95%	109.53%
Invested Capital Growth	-7.68%	-9.85%	76.48%	73.93%	67.70%	79.88%	8.11%	7.30%	13.31%	4.16%	-6.07%
Revenue Q/Q Growth	-10.31%	6.86%	1.37%	12.64%	-9.14%	18.73%	-1.19%	14.43%	-10.73%	2.81%	0.88%
EBITDA Q/Q Growth	39.54%	-44.51%	75.65%	39.30%	-29.41%	-15.22%	10.39%	-33.22%	58.91%	-14.54%	33.87%
EBIT Q/Q Growth	76.32%	-60.56%	142.01%	111.90%	-54.81%	-38.17%	14.37%	-40.63%	84.23%	-21.63%	48.47%
NOPAT Q/Q Growth	-44.26%	-0.81%	4.15%	158.55%	-39.37%	-36.28%	-21.69%	44.63%	-23.09%	-13.49%	27.31%
Net Income Q/Q Growth	175.92%	-77.84%	279.36%	760.18%	-114.73%	-55.66%	25.45%	-51.46%	75.80%	-24.59%	62.72%
EPS Q/Q Growth	173.50%	-77.59%	278.26%	757.14%	-114.79%	-55.90%	25.29%	-51.33%	76.00%	-24.62%	62.45%
Operating Cash Flow Q/Q Growth	-70.84%	33.60%	45.22%	256.89%	28.07%	-80.51%	-32.83%	286.18%	-59.83%	-11.05%	54.30%
Free Cash Flow Firm Q/Q Growth	-27.89%	132.76%	-1.13%	-0.60%	8.63%	-3,494.20%	-2,645.88%	99.00%	-450.86%	-83.27%	43.07%
Invested Capital Q/Q Growth	1.44%	-8.34%	-0.60%	-0.11%	-0.95%	79.44%	-2.04%	-3.69%	6.25%	7.84%	-2.77%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Gross Margin	63.58%	65.75%	61.07%	61.42%	57.03%	62.03%	73.84%	74.05%	71.83%	74.46%	76.13%
EBITDA Margin	50.10%	32.20%	62.01%	35.79%	28.94%	37.25%	52.17%	46.69%	80.02%	44.95%	54.07%
Operating Margin	14.46%	25.43%	24.07%	22.76%	13.31%	15.51%	29.28%	38.42%	31.47%	32.61%	39.99%
EBIT Margin	33.08%	16.83%	45.60%	19.10%	10.15%	20.41%	39.20%	33.87%	65.27%	31.63%	41.49%
Profit (Net Income) Margin	21.23%	6.90%	33.28%	8.89%	-1.52%	9.36%	25.06%	19.74%	46.54%	23.63%	32.22%
Tax Burden Percent	87.68%	80.18%	91.26%	93.95%	166.18%	90.02%	88.85%	85.44%	82.54%	92.45%	89.59%
Interest Burden Percent	73.18%	51.14%	79.98%	49.56%	-8.99%	50.93%	71.95%	68.22%	86.37%	80.81%	86.67%
Effective Tax Rate	12.32%	19.82%	8.74%	6.05%	0.00%	9.98%	11.15%	14.56%	17.46%	7.55%	10.41%
Return on Invested Capital (ROIC)	7.58%	11.97%	15.49%	14.17%	5.81%	8.45%	21.72%	26.51%	20.42%	24.31%	29.59%
ROIC Less NNEP Spread (ROIC-NNEP)	8.94%	9.56%	17.98%	11.57%	3.90%	7.54%	21.48%	23.28%	24.58%	22.69%	28.67%
Return on Net Nonoperating Assets (RNNOA)	81.88%	80.37%	91.34%	73.46%	31.69%	63.49%	100.56%	143.31%	236.84%	120.26%	125.30%
Return on Equity (ROE)	89.46%	92.33%	106.82%	87.63%	37.50%	71.93%	122.29%	169.82%	257.26%	144.57%	154.89%
Cash Return on Invested Capital (CROIC)	19.63%	21.67%	-43.14%	-42.20%	-37.84%	-42.59%	16.04%	17.98%	10.96%	22.07%	33.00%
Operating Return on Assets (OROA)	12.38%	5.95%	16.35%	6.52%	3.30%	7.09%	13.64%	12.04%	23.12%	13.18%	16.98%
Return on Assets (ROA)	7.95%	2.44%	11.94%	3.04%	-0.49%	3.25%	8.72%	7.02%	16.48%	9.85%	13.18%
Return on Common Equity (ROCE)	89.46%	92.33%	106.82%	87.63%	37.50%	71.93%	122.29%	169.82%	257.26%	144.57%	154.89%
Return on Equity Simple (ROE_SIMPLE)	95.59%	0.00%	56.20%	52.83%	74.93%	0.00%	98.82%	117.67%	148.04%	0.00%	187.11%
Net Operating Profit after Tax (NOPAT)	1,033	1,853	1,868	1,794	694	1,144	1,796	2,293	1,586	2,062	2,383
NOPAT Margin	12.68%	20.39%	21.97%	21.38%	9.32%	13.96%	26.01%	32.83%	25.97%	30.14%	35.83%
Net Nonoperating Expense Percent (NNEP)	-1.36%	2.41%	-2.49%	2.60%	1.91%	0.91%	0.25%	3.23%	-4.16%	1.62%	0.93%
Return On Investment Capital (ROIC_SIMPLE)	1.62%	2.81%	-	-	-	1.62%	-	-	-	4.84%	-
Cost of Revenue to Revenue	36.42%	34.25%	38.93%	38.58%	42.97%	37.97%	26.16%	25.95%	28.17%	25.54%	23.87%
SG&A Expenses to Revenue	30.89%	23.40%	19.11%	21.28%	24.28%	38.47%	19.60%	18.52%	20.61%	30.34%	19.35%
R&D to Revenue	18.24%	18.97%	17.05%	17.25%	18.03%	18.72%	15.63%	15.93%	17.33%	19.36%	16.72%
Operating Expenses to Revenue	49.12%	40.31%	37.00%	38.66%	43.72%	46.52%	44.56%	35.63%	40.36%	41.85%	36.14%
Earnings before Interest and Taxes (EBIT)	2,696	1,529	3,877	1,602	756	1,673	2,706	2,366	3,985	2,163	2,760
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	4,083	2,926	5,273	3,002	2,155	3,053	3,601	3,262	4,885	3,074	3,597
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	26.96	23.65	23.00	28.09	29.88	23.82	18.23	16.85	23.03	35.62	31.00
Price to Tangible Book Value (P/TBV)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Price to Revenue (P/Rev)	4.90	4.16	5.32	5.38	5.08	5.27	5.20	4.30	4.70	4.95	4.30
Price to Earnings (P/E)	28.21	33.98	40.93	53.18	39.87	22.10	18.45	14.32	15.56	19.91	16.57
Dividend Yield	2.93%	3.48%	2.76%	2.82%	3.08%	3.07%	3.19%	3.81%	3.45%	3.17%	3.58%
Earnings Yield	3.54%	2.94%	2.44%	1.88%	2.51%	4.53%	5.42%	6.98%	6.43%	5.02%	6.04%
Enterprise Value to Invested Capital (EV/IC)	3.94	3.46	3.81	3.71	3.44	3.37	4.95	4.15	4.33	4.81	4.55
Enterprise Value to Revenue (EV/Rev)	6.33	5.60	6.90	7.11	6.92	7.17	6.16	5.32	5.85	6.08	5.33
Enterprise Value to EBITDA (EV/EBITDA)	14.13	14.01	16.65	18.61	16.93	13.65	11.15	9.55	10.76	13.15	11.32
Enterprise Value to EBIT (EV/EBIT)	22.25	24.10	28.39	32.62	27.24	18.83	14.73	12.55	14.23	18.29	15.51
Enterprise Value to NOPAT (EV/NOPAT)	32.51	29.05	39.94	39.98	33.87	29.93	21.59	17.18	19.62	18.76	16.48
Enterprise Value to Operating Cash Flow (EV/OCF)	17.71	16.28	30.94	34.10	25.24	23.86	15.62	13.11	17.77	16.47	14.22
Enterprise Value to Free Cash Flow (EV/FCFF)	19.28	15.16	0.00	0.00	0.00	0.00	32.08	23.91	41.95	22.22	13.35
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Debt to Equity	9.24	10.23	8.02	10.57	12.75	10.37	7.90	9.08	11.52	10.64	10.60
Long-Term Debt to Equity	8.70	9.62	7.55	9.64	11.96	10.14	7.71	8.76	11.36	10.20	10.17
Financial Leverage	9.16	8.41	5.08	6.35	8.13	8.42	4.68	6.16	9.63	5.30	4.37
Leverage Ratio	16.24	15.61	11.95	14.26	17.52	16.40	13.64	16.26	23.61	12.19	10.84
Compound Leverage Factor	11.88	7.98	9.56	7.07	-1.58	8.35	9.81	11.09	20.40	9.85	9.40
Debt to Total Capital	90.24%	91.09%	88.92%	91.36%	92.73%	91.20%	88.76%	90.08%	92.01%	91.41%	91.38%
Short-Term Debt to Total Capital	5.30%	5.38%	5.22%	8.06%	5.73%	2.04%	2.10%	3.17%	1.25%	3.73%	3.64%
Long-Term Debt to Total Capital	84.94%	85.71%	83.70%	83.30%	86.99%	89.17%	86.67%	86.90%	90.77%	87.67%	87.73%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	9.76%	8.91%	11.08%	8.64%	7.27%	8.80%	11.24%	9.92%	7.99%	8.59%	8.62%
Debt to EBITDA	3.75	4.50	4.48	5.30	5.30	4.37	4.08	4.15	4.32	3.20	3.12
Net Debt to EBITDA	3.18	3.60	3.81	4.52	4.50	3.63	1.74	1.84	2.11	2.44	2.19
Long-Term Debt to EBITDA	3.53	4.23	4.22	4.84	4.98	4.27	3.98	4.01	4.27	3.07	2.99
Debt to NOPAT	8.64	9.33	10.74	11.39	10.61	9.57	7.90	7.47	7.89	4.56	4.54
Net Debt to NOPAT	7.31	7.47	9.14	9.70	9.00	7.95	3.36	3.31	3.85	3.47	3.19
Long-Term Debt to NOPAT	8.13	8.78	10.11	10.39	9.95	9.35	7.71	7.21	7.78	4.38	4.36
Altman Z-Score	1.32	1.05	1.44	1.23	1.06	1.09	1.44	1.21	1.32	1.29	1.25
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Current Ratio	1.17	1.26	1.32	1.26	1.42	1.65	2.86	2.77	3.14	1.41	1.68
Quick Ratio	0.74	0.81	0.80	0.75	0.84	0.99	2.41	2.34	2.62	0.95	1.17
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	5,589	7,751	-23,663	-23,398	-23,258	-25,456	-708	-26	-2,570	733	4,379
Operating Cash Flow to CapEx	338.44%	1,285.98%	1,389.49%	1,033.19%	299.57%	216.06%	1,112.90%	1,516.24%	309.30%	779.12%	1,861.25%
Free Cash Flow to Firm to Interest Expense	7.73	10.38	-30.49	-28.96	-28.23	-31.01	-0.93	-0.03	-4.73	1.77	11.90
Operating Cash Flow to Interest Expense	1.92	6.39	4.60	3.04	0.84	0.66	3.64	5.46	1.96	6.38	8.09
Operating Cash Flow Less CapEx to Interest Expense	1.36	5.89	4.27	2.75	0.56	0.35	3.31	5.10	1.33	5.56	7.66
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.37	0.35	0.36	0.34	0.33	0.35	0.35	0.36	0.35	0.42	0.41
Accounts Receivable Turnover	4.58	4.76	4.83	4.85	4.72	4.39	4.68	4.77	4.84	5.03	5.22
Inventory Turnover	1.63	1.56	2.08	1.75	1.45	1.17	1.45	1.44	1.39	1.42	1.43
Fixed Asset Turnover	5.38	5.35	5.55	5.32	5.15	4.96	4.99	4.97	4.94	4.96	5.18
Accounts Payable Turnover	6.26	7.35	7.34	6.53	6.74	5.35	5.53	5.57	4.82	4.36	5.37
Days Sales Outstanding (DSO)	79.73	76.72	75.52	75.30	77.32	83.07	78.02	76.60	75.35	72.51	69.94
Days Inventory Outstanding (DIO)	223.36	234.42	175.83	208.52	252.41	312.01	251.96	253.29	261.92	256.86	254.96
Days Payable Outstanding (DPO)	58.31	49.65	49.75	55.92	54.17	68.28	65.98	65.58	75.70	83.70	67.97
Cash Conversion Cycle (CCC)	244.78	261.49	201.60	227.91	275.55	326.79	263.99	264.31	261.57	245.66	256.94
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	54,778	54,003	58,914	59,269	59,334	59,901	33,383	34,077	35,382	33,301	30,879
Invested Capital Turnover	0.60	0.59	0.71	0.66	0.62	0.60	0.84	0.81	0.79	0.81	0.83
Increase / (Decrease) in Invested Capital	-4,556	-5,898	25,531	25,192	23,952	26,600	2,504	2,319	4,156	1,329	-1,996
Enterprise Value (EV)	215,937	187,106	224,520	219,794	204,356	202,091	165,289	141,538	153,184	160,059	140,467
Market Capitalization	167,366	138,980	173,133	166,450	150,044	148,422	139,562	114,242	123,150	130,419	113,241
Book Value per Share	$11.55	$10.93	$14.01	$11.05	$9.37	$11.64	$14.31	$12.69	$10.02	$6.86	$6.83
Tangible Book Value per Share	($71.04)	($75.27)	($74.54)	($79.90)	($83.81)	($84.16)	($39.27)	($43.76)	($47.90)	($52.38)	($45.72)
Total Capital	63,588	65,976	67,925	68,570	69,042	70,845	68,124	68,325	66,943	42,606	42,357
Total Debt	57,381	60,099	60,398	62,645	64,020	64,613	60,468	61,544	61,595	38,945	38,704
Total Long-Term Debt	54,013	56,549	56,854	57,117	60,061	63,170	59,040	59,377	60,761	37,354	37,161
Net Debt	48,571	48,126	51,387	53,344	54,312	53,669	25,727	27,296	30,034	29,640	27,226
Capital Expenditures (CapEx)	411	371	257	238	230	249	248	271	344	340	160
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-1,521	-2,492	987	1,916	2,566	2,439	-1,790	-1,798	-239	-1,215	-204
Debt-free Net Working Capital (DFNWC)	7,289	9,481	9,998	11,217	12,274	13,383	32,951	32,450	31,322	8,090	11,274
Net Working Capital (NWC)	3,921	5,931	6,454	5,689	8,315	11,940	31,523	30,283	30,488	6,499	9,731
Net Nonoperating Expense (NNE)	-697	1,226	-962	1,048	807	377	66	914	-1,255	446	240
Net Nonoperating Obligations (NNO)	48,571	48,126	51,387	53,344	54,312	53,669	25,727	27,296	30,034	29,640	27,226
Total Depreciation and Amortization (D&A)	1,387	1,397	1,396	1,400	1,399	1,380	895	896	900	911	837
Debt-free, Cash-free Net Working Capital to Revenue	-4.46%	-7.46%	3.03%	6.19%	8.69%	8.65%	-6.67%	-6.76%	-0.91%	-4.62%	-0.77%
Debt-free Net Working Capital to Revenue	21.36%	28.37%	30.73%	36.26%	41.56%	47.47%	122.80%	122.08%	119.60%	30.73%	42.82%
Net Working Capital to Revenue	11.49%	17.74%	19.84%	18.39%	28.16%	42.36%	117.48%	113.92%	116.41%	24.69%	36.96%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	$3.22	$1.17	$5.27	$1.39	($0.21)	$1.43	$3.23	$2.58	$5.32	$3.02	$4.01
Adjusted Weighted Average Basic Shares Outstanding	538M	537M	537M	537M	536M	535M	535M	535M	534M	538M	535M
Adjusted Diluted Earnings per Share	$3.20	$1.17	$5.22	$1.38	($0.21)	$1.42	$3.22	$2.57	$5.28	$3.00	$3.98
Adjusted Weighted Average Diluted Shares Outstanding	541M	541M	542M	541M	536M	538M	538M	537M	538M	541M	538M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	537.71M	537.20M	537.53M	537.33M	536.43M	535.92M	535.18M	534.90M	534.33M	533.98M	533.58M
Normalized Net Operating Profit after Tax (NOPAT)	1,033	1,853	1,868	1,794	694	1,144	1,796	2,293	1,586	2,062	2,383
Normalized NOPAT Margin	12.68%	20.39%	21.97%	21.38%	9.32%	13.96%	26.01%	32.83%	25.97%	30.14%	35.83%
Pre Tax Income Margin	24.21%	8.61%	36.47%	9.47%	-0.91%	10.40%	28.21%	23.10%	56.38%	25.56%	35.96%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	3.73	2.05	5.00	1.98	0.92	2.04	3.57	3.15	7.34	5.21	7.50
NOPAT to Interest Expense	1.43	2.48	2.41	2.22	0.84	1.39	2.37	3.05	2.92	4.97	6.48
EBIT Less CapEx to Interest Expense	3.16	1.55	4.66	1.69	0.64	1.73	3.24	2.79	6.71	4.39	7.07
NOPAT Less CapEx to Interest Expense	0.86	1.98	2.08	1.93	0.56	1.09	2.04	2.69	2.29	4.15	6.04
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	82.64%	118.14%	112.70%	150.06%	122.96%	67.83%	58.90%	54.57%	53.72%	64.04%	60.66%
Augmented Payout Ratio	82.64%	123.03%	112.70%	150.06%	122.96%	67.83%	58.90%	54.57%	53.72%	161.11%	174.82%

Frequently Asked Questions About Amgen's Financials

When does Amgen's financial year end?

According to the most recent income statement we have on file, Amgen's fiscal year ends in December. Their fiscal year 2024 ended on December 31, 2024.

How has Amgen's net income changed over the last 9 years?

In the past 9 years, Amgen's net income has ranged from $1.98 billion in 2017 to $8.39 billion in 2018, and is currently $4.09 billion as of their latest financial filing in 2024. Check out Amgen's forecast to explore projected trends and price targets.

What is Amgen's operating income?

Amgen's total operating income in 2024 was $7.26 billion, based on the following breakdown:

Total Gross Profit: $20.57 billion
Total Operating Expenses: $13.31 billion

How has Amgen revenue changed over the last 9 years?

Over the last 9 years, Amgen's total revenue changed from $21.66 billion in 2015 to $33.42 billion in 2024, a change of 54.3%.

How much debt does Amgen have?

Amgen's total liabilities were at $85.96 billion at the end of 2024, a 5.5% decrease from 2023, and a 98.2% increase since 2015.

How much cash does Amgen have?

In the past 9 years, Amgen's cash and equivalents has ranged from $3.24 billion in 2016 to $11.97 billion in 2024, and is currently $11.97 billion as of their latest financial filing in 2024.

How has Amgen's book value per share changed over the last 9 years?

Over the last 9 years, Amgen's book value per share changed from 37.23 in 2015 to 10.93 in 2024, a change of -70.6%.

Related Companies

This page (NASDAQ:AMGN) was last updated on 5/29/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Amgen (AMGN) Financials

Frequently Asked Questions About Amgen's Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Amgen (AMGN) Financials

Annual Income Statements for Amgen

Quarterly Income Statements for Amgen

Annual Cash Flow Statements for Amgen

Quarterly Cash Flow Statements for Amgen

Annual Balance Sheets for Amgen

Quarterly Balance Sheets for Amgen

Annual Metrics And Ratios for Amgen

Quarterly Metrics And Ratios for Amgen

Frequently Asked Questions About Amgen's Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools